748 related articles for article (PubMed ID: 28285386)
1. Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Ann Hematol; 2017 May; 96(5):829-838. PubMed ID: 28285386
[TBL] [Abstract][Full Text] [Related]
2. Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs.-host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clinical outcomes.
Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Eur J Haematol; 2016 Mar; 96(3):297-308. PubMed ID: 26010204
[TBL] [Abstract][Full Text] [Related]
3. Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation.
Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1939-47. PubMed ID: 26116088
[TBL] [Abstract][Full Text] [Related]
4. Minimal residual disease-directed immunotherapy for high-risk myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Mo X; Zhang X; Xu L; Wang Y; Yan C; Chen H; Chen Y; Han W; Wang F; Wang J; Liu K; Huang X
Front Med; 2019 Jun; 13(3):354-364. PubMed ID: 30680605
[TBL] [Abstract][Full Text] [Related]
5. Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Yuan XL; Tan YM; Shi JM; Zhao YM; Yu J; Lai XY; Yang LX; Huang H; Luo Y
Ann Hematol; 2021 Feb; 100(2):517-527. PubMed ID: 33128124
[TBL] [Abstract][Full Text] [Related]
6. Interferon-α salvage treatment is effective for patients with acute leukemia/myelodysplastic syndrome with unsatisfactory response to minimal residual disease-directed donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation.
Mo X; Zhang X; Xu L; Wang Y; Yan C; Chen H; Chen Y; Han W; Wang F; Wang J; Liu K; Huang X
Front Med; 2019 Apr; 13(2):238-249. PubMed ID: 29656333
[TBL] [Abstract][Full Text] [Related]
7. [Effects of chemotherapy combined with donor lymphocyte infusion on chronic graft-versus-host disease and prognosis in minimal residual disease positive patients after allogeneic hematopoietic stem cell transplantation].
Shi YX; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YY; Liu KY; Huang XJ; Mo XD
Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):713-719. PubMed ID: 31648470
[No Abstract] [Full Text] [Related]
8. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia.
Yan CH; Liu QF; Wu DP; Zhang X; Xu LP; Zhang XH; Wang Y; Huang H; Bai H; Huang F; Ma X; Huang XJ
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1311-1319. PubMed ID: 28483716
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors.
Yan CH; Wang JZ; Liu DH; Xu LP; Chen H; Liu KY; Huang XJ
Eur J Haematol; 2013 Oct; 91(4):304-14. PubMed ID: 23837640
[TBL] [Abstract][Full Text] [Related]
10. Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant.
Yan CH; Wang Y; Wang JZ; Chen YH; Chen Y; Wang FR; Sun YQ; Mo XD; Han W; Chen H; Zhang XH; Xu LP; Liu KY; Huang XJ
J Hematol Oncol; 2016 Sep; 9(1):87. PubMed ID: 27629395
[TBL] [Abstract][Full Text] [Related]
11. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
[TBL] [Abstract][Full Text] [Related]
12. Occurrence and Severity of Donor Lymphocyte Infusion-Associated Chronic Graft-versus-Host Disease Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation.
Yu WJ; Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2019 May; 25(5):912-920. PubMed ID: 30485788
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of donor lymphocyte infusion in patients after different types of allogeneic hematopoietic stem cell transplantation].
Slesarchuk OA; Babenko EV; Semenova EV; Bondarenko SN; Éstrina MA; Morozova EV; Paina OV; Vavilov VN; Smirnov BI; Zubarovskaia LS; Afanas'ev BV
Ter Arkh; 2013; 85(7):26-33. PubMed ID: 24137944
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppression for 6-8 weeks after modified donor lymphocyte infusion reduced acute graft-versus-host disease without influencing graft-versus-leukemia effect in haploidentical transplant.
Yan C; Xu L; Liu D; Chen H; Wang Y; Liu K; Huang X
Chin Med J (Engl); 2014; 127(20):3602-9. PubMed ID: 25316237
[TBL] [Abstract][Full Text] [Related]
15. Superiority of preemptive donor lymphocyte infusion based on minimal residual disease in acute leukemia patients after allogeneic hematopoietic stem cell transplantation.
Tan Y; Du K; Luo Y; Shi J; Cao L; Zheng Y; Zheng G; Zhao Y; Ye X; Cai Z; Huang H
Transfusion; 2014 Jun; 54(6):1493-500. PubMed ID: 24372162
[TBL] [Abstract][Full Text] [Related]
16. Low-dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical HSCT.
Yan CH; Xu LP; Liu DH; Chen H; Wang Y; Wang JZ; Wang FR; Han W; Liu KY; Huang XJ
Clin Transplant; 2015 Jul; 29(7):594-605. PubMed ID: 25969866
[TBL] [Abstract][Full Text] [Related]
17. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 May; 98(5):1267-1277. PubMed ID: 30747249
[TBL] [Abstract][Full Text] [Related]
19. Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors.
Yan CH; Liu DH; Xu LP; Liu KY; Zhao T; Wang Y; Chen H; Chen YH; Han W; Huang XJ
Clin Transplant; 2012; 26(6):868-76. PubMed ID: 22432715
[TBL] [Abstract][Full Text] [Related]
20. Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.
Davies JK; Hassan S; Sarker SJ; Besley C; Oakervee H; Smith M; Taussig D; Gribben JG; Cavenagh JD
Br J Haematol; 2018 Feb; 180(3):346-355. PubMed ID: 29076145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
